Decreased Bone Mineral Density in Adult Patients with Hemophilia: Clinical Significance, Prevalence and Risk Factors
Back to listIntroduction
Osteoporosis is widely recognized as a major health issue, and tremendous resources are spent screening, diagnosing, and treating this disease in postmenopausal women. According to the National Institutes of Health (NIH) Consensus Development Panel on Osteoporosis, 10 million people in the USA have osteoporosis and almost twice as many have decreased bone mass (1). Osteoporosis is defined as a decline in bone density and bone quality resulting in an increased risk for fragility fractures 1. It can be separated into primary osteoporosis resulting from gradual bone loss with aging and secondary osteoporosis due to a variety of medical disorders including chronic corticosteroid use, hypogonadism, alcoholism, and hyperthyroidism. The final common pathway for both primary and secondary causes of osteoporosis is increased bone resorption in relation to new bone formation.
Abstract
Osteoporosis is widely recognized as a major health problem, and considerable resources are spent screening, diagnosing, and treating this disease in postmenopausal women. Adults with hemophilia have unique factors that place them at an increased risk for developing osteoporosis including periods of immobilization after bleeds, impaired joint mobility that may limit weight bearing physical activity, and infection with Hepatitis C virus (HCV) and/or human immunodeficiency virus (HIV). Several publications report the prevalence of osteoporosis in adults with hemophilia to be in the range of 25% and 50%. The severity of hemophilic joint arthropathy appears to be the strongest predictor of significant bone loss in patients with hemophilia. The relative contribution of other risk factors, including HIV and HCV infection are less well defined. The clinical significance of decreased bone mineral density as measured by dual energy X-ray absorptiometry (DXA) to fracture risk in men, and in particular younger men, is also unclear. We recommend screening adult patients with hemophilia with documented fragility fractures, in those with severe joint arthropathy, and in those patients >50 years of age with additional risk factors such as HIV/HCV infection or low BMI. Adequate vitamin D and calcium intake, weight bearing physical activity, and interventions to maintain joint mobility are recommended for all hemophilia patients. The role of pharmacologic agents, including bisphosphonates, is untested, and they should be reserved for those with documented osteoporosis and fragility fractures or additional risk factors that place them at high risk for developing fragility fractures.
Keywords
hemophilia, joint arthropathy, osteoporosis, osteopenia, bone mineral density, fragility fracture
Other Articles
- Effect of Adjusted and Non-Adjusted Citrate Concentrations on Coagulation Test Results in Patients With High Hematocrit Values—Breaking the Unproven Leap of Faith
- The Off-Label Use of Recombinant FVIIa in the Treatment of a Patient With T-Cell Non-Hodgkin Lymphoma Who Developed Intra-abdominal and Intra-Pleural Hemorrhages Followed by High-Dose Methotreaxate Therapy
- Prophylaxis with Once, Twice or Three-Times Weekly Dosing of rFVIII-FS prevents Joint Bleeds in a Previously Treated Pediatric Population with Moderate/Severe Hemophilia A
- Current Practice in Clinical Thrombosis and Hemostasis
- Review of the Literature of FEIBA Administration in Patients with Hemophilia B and Inhibitors
